Story perspectives

Zoldonrasib Shows 52% Response Rate in Lung Cancer Trial

4/21/2026

Summary

Story summary

A Phase I study presented at the American Association for Cancer Research annual meeting shows zoldonrasib achieved a 52% objective response rate and 93% disease control in KRAS G12D-mutated NSCLC.
The study involved patients previously treated with immune checkpoint inhibitors and platinum-based chemotherapy.
Progression-free survival was 11.1 months.
Zoldonrasib targets the active state of KRAS G12D and addresses the limited and toxic options.
Further evaluation in combination therapies is recommended.

1 of 1

Story summary

A Phase I study presented at the American Association for Cancer Research annual meeting shows zoldonrasib achieved a 52% objective response rate and 93% disease control in KRAS G12D-mutated NSCLC.
The study involved patients previously treated with immune checkpoint inhibitors and platinum-based chemotherapy.
Progression-free survival was 11.1 months.
Zoldonrasib targets the active state of KRAS G12D and addresses the limited and toxic options.
Further evaluation in combination therapies is recommended.